Drug news

GSK returns US rights of Horizant to Xenoport

Read time: 1 mins

Last updated:10th Nov 2012

Published:10th Nov 2012

Source: Pharmawand

GlaxoSmithKline (GSK) plc announced that it has reached an agreement with XenoPort, Inc., to terminate their collaboration concerning Horizant (gabapentin enacarbil) Extended-Release Tablets, a treatment for Restless legs, for which GSK had commercialisation rights and certain development rights in the United States. Under the termination and transition agreement, GSK is returning Horizant rights to XenoPort and providing certain assistance during the transition period ending April 30, 2013, upon mutually agreed terms.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Positive data for V116, an investigational, 21-valent pneumococcal conjugate vaccine specifically designed for adults

Merck Inc., known as MSD outside of the United States and Canada, announced results from STRIDE-10, a Phase III trial evaluating V116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine, at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in Barcelona, Spain

3 mins

Drug news

Stenoparib shows clear clinical benefit and achieves significant milestone with early conclusion of phase II trial in advanced ovarian cancer

Allarity Therapeutics, Inc. announced the early discontinuation of its Phase II clinical trial of stenoparib, a novel PARP inhibitor, for the treatment of advanced recurrent ovarian cancer

2 min

Drug news

Calquence (acalabrutinib)combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial

Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s Calquence (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care in previously untreated adult patients with mantle cell lymphoma (MCL)

2 min

See all news